QUICK LINKS
SEE ALSO...
SK-MEL-28 + IFN-γ cell lysate results from treating the human melanoma cell line SK-MEL-28 with interferon-gamma (IFN-γ), a cytokine known for its role in immune response modulation. This specific lysate is pivotal in research focused on understanding the interaction between tumor cells and immune signaling. IFN-γ treatment in melanoma cells like SK-MEL-28 has been shown to induce changes in the expression of immune regulatory molecules, including MHC class I and II proteins, making these cells more recognizable to the immune system. Researchers utilize this lysate to explore how IFN-γ alters signaling pathways within melanoma cells, particularly looking at pathways involved in immune evasion, cell survival, and apoptosis. This includes studying the JAK-STAT pathway, which is directly activated by IFN-γ and plays a critical role in mediating its effects. Additionally, this cell lysate aids in examining the upregulation of PD-L1, a mechanism that tumors may use to suppress the immune response. Utilizing SK-MEL-28 + IFN-γ cell lysate enables scientists to dissect these complex mechanisms in a controlled research setting, providing valuable insights into the cellular responses to cytokine exposure. This research contributes fundamentally to the understanding of melanoma immunology.
Ordering Information
Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SK-MEL-28 + IFN-γ Cell Lysate | sc-2291 | 500 µg/200 µl | $118.00 |